ATMP XB Project 

Advancing ATMP Development

We are excited to be part of the ATMP XB project, a cross-border initiative in the Flemish-Dutch region focused on strengthening the development and delivery of Advanced Therapy Medicinal Products (ATMPs). These therapies—including cell and gene therapies—offer new treatment options for patients with severe or life-threatening diseases.

Addressing Key Challenges

ATMP XB tackles critical gaps in quality control, sterility testing, and scalable GMP practices. Through the development of a networked QA/QC competence centre and expanded infrastructure, the project aims to increase testing capacity, improve reliability, and support developers in bringing therapies to patients more efficiently.

Driving Innovation and Collaboration

Beyond infrastructure, the project focuses on advancing new technologies, supporting companies in overcoming development hurdles, and contributing to skills development through training and knowledge-sharing initiatives. By strengthening cross-border collaboration, ATMP XB helps build a more connected and robust ATMP ecosystem in Europe.

A Strong European Partnership

Co-funded by the European Union under the Interreg Vlaanderen-Nederland programme, ATMP XB represents a €3.5 million investment in innovation.

IDEVAX is a key partner in ATMP XB, contributing alongside a strong cross-border consortium led by Biovia. The partnership includes POM Antwerpen, at.las ATMP, Smart BioMaterials Center (SBMC), anicells, QbD Group, Karel de Grote-Hogeschool, UZ Gent, Anabiotec, RegMed XB, and Sure Laboratories.

Together, these organizations bring expertise from research, industry, and healthcare to drive innovation and strengthen the ATMP ecosystem.